CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Dexcom Q3 revenue slightly beats; $1 bln share buyback announced

By Reuters News


Overview

  • Glucose biosensing firm's Q3 revenue grew 11% yr/yr, slightly beating analyst expectations

  • Adjusted EPS for Q3 beat analyst expectations

  • Company announced $1.0 bln share repurchase authorization


Outlook

  • Dexcom raises 2026 revenue guidance to $5.20-$5.25 bln, up 12-13% year-over-year

  • Company expects 2026 non-GAAP gross profit margin of about 64%

  • Dexcom sees 2026 non-GAAP operating margin of about 24% and adjusted EBITDA margin of about 32%


Result Drivers

  • US GROWTH - Co said Q3 revenue growth was led by 14% yr/yr increase in US sales

  • PRODUCT UPDATES - Co cited launch of redesigned Stelo experience with new features as a driver

  • PRODUCT ROLLOUT - Co advanced rollout of Dexcom G7 15 Day System in US and gained initial international clearances


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$1.34 bln

$1.33 bln (24 Analysts)

Q3 Adjusted EPS

Beat

$0.73

$0.67 (23 Analysts)

Q3 Adjusted Net Income

Beat

$275.1 mln

$256.55 mln (20 Analysts)

Q3 Adjusted Operating Income

Beat

$339.5 mln

$314.20 mln (23 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Dexcom Inc is $95.00, about 20.8% above its October 28 closing price of $78.62

  • The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 24 three months ago


Reuters Recommended Reads

  • Oct 28 - Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

  • Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.